Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 41, 2021 - Issue 4
Submit an article Journal homepage
197
Views
6
CrossRef citations to date
0
Altmetric
Original Articles: Gynaecology

To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy

Archana Kumaria Department of Obstetrics & Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Monika Thakurb Department of Obstetrics & Gynaecology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6918-5133
ORCID Icon,
S. C. Sahaa Department of Obstetrics & Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Vanita Suria Department of Obstetrics & Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
G. R. V. Prasada Department of Obstetrics & Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Firuza D. Patelc Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India
&
S. Radhikad Department of Cytology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
 show all
Pages 616-620 | Published online: 19 Aug 2020

References

  • Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. 2011. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecologic Oncology 120:23–28.
  • Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. 2001. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91:2329–2334.
  • Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A. 2016. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecologic Oncology 142:597–607.
  • Da Costa Miranda V, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, et al. 2014. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecologic Oncology 132:287–291.
  • Katabuchi H. 2017. Frontiers in ovarian cancer science. Singapore (Singapore): Springer.
  • Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, et al. 2018. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Radiology and Oncology 52:307–319.
  • Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. 2015. Neoadjuvant chemotherapy in gynaecological cancers - implications for staging. Best Practice & Research Clinical Obstetrics & Gynaecology 29:790–801.
  • Ozols RF. 2000. Epithelial ovarian cancer. Principles and practice of gynecologic oncology, 3rd ed. Lippincott Williams & Wilkins.
  • Stoeckle E, Boubli B, Floquet A, Brouste V, Sire M, Croce S, et al. 2011. Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? European Journal of Obstetrics, Gynecology, and Reproductive Biology 159:407–412.
  • Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, et al. 2014. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology 21:629–636.
  • Vergote CG, Trope F, Amant GB. 2008. EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage III C –IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th Biennial meeting. International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25–28.
  • Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. 2007. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology 106:69–74.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.